Details about Diana B. De Graeve

Access statistics for papers by Diana B. De Graeve.

Last updated 2022-10-17. Update your information in the RePEc Author Service.

Short-id: pde679

Working Papers

2010

1. Supplemental health insurance and equality of access in Belgium
   LIDAM Reprints CORE, Université catholique de Louvain, Center for Operations Research and Econometrics (CORE) View citations (18)
   See also Journal Article Supplemental health insurance and equality of access in Belgium, Health Economics, John Wiley & Sons, Ltd. (2010) View citations (21) (2010)

2007

2. Comparing the cost-effectiveness of Haloperidol, Risperidone and Olanzapine in the treatment of schizophrenia using the net-benefit regression approach
   Working Papers, University of Antwerp, Faculty of Business and Economics View citations (2)

2002

3. Order bias in estimates of willingness to pay for drugs to treat Attention-Deficit/Hyperactivity Disorder. A contingent valuation study among students
   Working Papers, University of Antwerp, Faculty of Business and Economics

2001

4. Socio-economische determinanten van medische consumptie: Analyse gezondheidsenquête 1997
   Working Papers, University of Antwerp, Faculty of Business and Economics View citations (1)
5. Wie valt er door de mazen van het net? Verkennend profiel van de patiënt met betalingsproblemen in het ziekenhuis
   Working Papers, University of Antwerp, Faculty of Business and Economics View citations (1)

2000

6. Toegankelijkheid verzekerd? Doorlichting van de regelgeving van de verzekering voor geneeskundige verzorging in België
   Working Papers, University of Antwerp, Faculty of Business and Economics

1997

7. Een economische evaluatie van het pneumokokkenvaccin voor België
   SESO Working Papers, University of Antwerp, Faculty of Business and Economics
8. Equity in health and in medical care consumption in Belgium
   SESO Working Papers, University of Antwerp, Faculty of Business and Economics View citations (4)

1994

9. De economische kosten van AIDS en HIV-infectie in België. Een situatieschets voor 1993
   SESO Working Papers, University of Antwerp, Faculty of Business and Economics
10. Pharmacoeconomic studies: Pitfalls and problems
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics View citations (1)
11. Ziekteverzuim en het toekennen van arbeidsongeschiktheid
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1992

12. Laboratory testing in the general practitioner's office: Economic consequences
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1991

13. A cost-effectiveness analysis of AOTAL, a drug used to prevent relapse in weaned alcoholics
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1990

14. Economische evaluatie van in-vitro fertilisatie
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1989

15. Costs, benefits and effects on prescribing of a drug information campaign. An experiment with respect to Benzodiazepines
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics
16. Lezersonderzoek naar de geneesmiddelenwijzer
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1988

17. Geneesmiddeleninformatie voor de arts: Evaluatie van het gebruik van het gecommentarieerd geneesmiddelenrepertorium
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics
18. Het prijscriterium in het voorschrijfgedrag van huisartsen
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

1985

19. Patiënten en hun raadplegingen van huisartsen en specialisten: Een toepassing van het model van Grossman
    SESO Working Papers, University of Antwerp, Faculty of Business and Economics

Undated

20. Economic analysis of the use of drug-eluting stents in the perspective of the Belgian health care sector
    Working Papers, University of Antwerp, Faculty of Business and Economics

Journal Articles

2022

1. Cost effects of nurse led triage at an emergency department with the advice to consult the adjacent general practice cooperative for low-risk patients, a cluster randomised trial
   Health Policy, 2022, 126, (10), 980-987

2012

2. Predicting the place of out-of-hours care—A market simulation based on discrete choice analysis
   Health Policy, 2012, 106, (3), 284-290 View citations (5)

2010

3. Supplemental health insurance and equality of access in Belgium
   Health Economics, 2010, 19, (4), 377-395 View citations (21)
   See also Working Paper Supplemental health insurance and equality of access in Belgium, LIDAM Reprints CORE (2010) View citations (18) (2010)

2009

4. Hospital supplements in Belgium: Price variation and regulation
   Health Policy, 2009, 92, (2-3), 276-287 View citations (4)

2005

5. Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder
   The European Journal of Health Economics, 2005, 6, (2), 146-151 View citations (1)

2003

6. The Distributional Impact of Health Financing in Europe: A Review
   The World Economy, 2003, 26, (10), 1459-1479 View citations (14)

2002

7. A typology for provider payment systems in health care
   Health Policy, 2002, 60, (3), 255-273 View citations (47)

2000

8. Equity in the delivery of health care in Europe and the US
   Journal of Health Economics, 2000, 19, (5), 553-583 View citations (167)
9. Financiële verantwoordelijkheid en betaalbaarheid van de gezondheidszorg
   Economic and Social Journal (Economisch en Sociaal Tijdschrift), 2000, 54, (2), 139-164

1998

10. Antibiotica-uitgaven: Een analyse van consumptie en prijzen. Een casestudy tegen de achtergrond van een veranderende ziekenhuisfinanciering
    Economic and Social Journal (Economisch en Sociaal Tijdschrift), 1998, 52, (1), 117-146
11. Bezoldigingen van alumni Toegepaste Economische Wetenschappen en Handelsingenieur
    Economic and Social Journal (Economisch en Sociaal Tijdschrift), 1998, 52, (4), 585-608

1997

12. Patient classification and cost analysis of aids and HIV: the case of Belgium
    Health Policy, 1997, 39, (2), 93-106 View citations (1)

1996

13. Kosten van ziekteverzuim op bedrijfsniveau
    Economic and Social Journal (Economisch en Sociaal Tijdschrift), 1996, 50, (3), 459-481